BioCentury | Feb 22, 2018
Finance

Belgian Insights

...Founder and Chairman of Strategy Committee, Biocartis Group N.V., Former Founder, Chairman and CEO/CSO of Tibotec N.V....
BioCentury | Jul 14, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson’s Tibotec...
BioCentury | Apr 7, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson's Tibotec...
BioCentury | Dec 23, 2013
Clinical News

Complera regulatory update

...in antiretroviral treatment-naïve adult patients with a viral load of <=100,000 copies/mL. Johnson & Johnson's Tibotec...
BioCentury | Nov 4, 2013
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...data provided were not sufficient to recommend approval (see BioCentury, Aug. 5). Johnson & Johnson's Tibotec...
BioCentury | Aug 5, 2013
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...said could increase the risk of resistance to Eviplera and similar treatments. Johnson & Johnson's Tibotec...
BioCentury | Dec 10, 2012
Clinical News

Complera: Phase IIIb data

...were presented at the Drug Therapy in HIV Infection meeting in Glasgow. Johnson & Johnson's Tibotec...
BioCentury | Sep 24, 2012
Strategy

Where innovation lives

...with product discovery and development out there," said Stoffels, who was CEO of virology company Tibotec-Virco...
BioCentury | Sep 3, 2012
Clinical News

Stribild elvitegravir/cobicistat/emtricitabine/tenofovir regulatory update

...$22,000 for Complera. Gilead co-markets Atripla with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). The Tibotec...
BioCentury | Aug 6, 2012
Clinical News

GS-7340/darunavir/cobicistat/emtricitabine: Phase II started

...markets Prezista, a second-generation protease inhibitor. Last November, Gilead and the Janssen R&D Ireland (formerly Tibotec...
Items per page:
1 - 10 of 257
BioCentury | Feb 22, 2018
Finance

Belgian Insights

...Founder and Chairman of Strategy Committee, Biocartis Group N.V., Former Founder, Chairman and CEO/CSO of Tibotec N.V....
BioCentury | Jul 14, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson’s Tibotec...
BioCentury | Apr 7, 2014
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson's Tibotec...
BioCentury | Dec 23, 2013
Clinical News

Complera regulatory update

...in antiretroviral treatment-naïve adult patients with a viral load of <=100,000 copies/mL. Johnson & Johnson's Tibotec...
BioCentury | Nov 4, 2013
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...data provided were not sufficient to recommend approval (see BioCentury, Aug. 5). Johnson & Johnson's Tibotec...
BioCentury | Aug 5, 2013
Clinical News

Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

...said could increase the risk of resistance to Eviplera and similar treatments. Johnson & Johnson's Tibotec...
BioCentury | Dec 10, 2012
Clinical News

Complera: Phase IIIb data

...were presented at the Drug Therapy in HIV Infection meeting in Glasgow. Johnson & Johnson's Tibotec...
BioCentury | Sep 24, 2012
Strategy

Where innovation lives

...with product discovery and development out there," said Stoffels, who was CEO of virology company Tibotec-Virco...
BioCentury | Sep 3, 2012
Clinical News

Stribild elvitegravir/cobicistat/emtricitabine/tenofovir regulatory update

...$22,000 for Complera. Gilead co-markets Atripla with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). The Tibotec...
BioCentury | Aug 6, 2012
Clinical News

GS-7340/darunavir/cobicistat/emtricitabine: Phase II started

...markets Prezista, a second-generation protease inhibitor. Last November, Gilead and the Janssen R&D Ireland (formerly Tibotec...
Items per page:
1 - 10 of 257